Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Profound Medical (PROF) Cash & Equivalents (2023 - 2025)

Profound Medical has reported Cash & Equivalents over the past 3 years, most recently at $59.7 million for Q4 2025.

  • Quarterly results put Cash & Equivalents at $59.7 million for Q4 2025, up 8.76% from a year ago — trailing twelve months through Dec 2025 was $59.7 million (up 8.76% YoY), and the annual figure for FY2025 was $59.7 million, up 8.76%.
  • Cash & Equivalents for Q4 2025 was $59.7 million at Profound Medical, up from $24.8 million in the prior quarter.
  • Over the last five years, Cash & Equivalents for PROF hit a ceiling of $59.7 million in Q4 2025 and a floor of $24.8 million in Q3 2025.
  • Median Cash & Equivalents over the past 3 years was $40.8 million (2025), compared with a mean of $41.2 million.
  • Biggest five-year swings in Cash & Equivalents: skyrocketed 109.48% in 2024 and later rose 8.76% in 2025.
  • Profound Medical's Cash & Equivalents stood at $26.2 million in 2023, then surged by 109.48% to $54.9 million in 2024, then grew by 8.76% to $59.7 million in 2025.
  • The last three reported values for Cash & Equivalents were $59.7 million (Q4 2025), $24.8 million (Q3 2025), and $35.2 million (Q2 2025) per Business Quant data.